Human induced pluripotent stem cell (iPSC)-derived models are transforming ALS research by providing a more accurate representation of disease phenotypes. Precision-reprogrammed iPSC-derived neurons ...
FT819 CAR T-cell Product Candidate Derived from Clonal Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus Phase 1 Clinical Study will Evaluate FT819 for Patients with ...
Biomedical research depends on the use of model systems to explore basic biology, probe disease mechanisms, and conduct drug discovery and development. However, results from such systems are often not ...
Cambridge, MA USA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned, independently operated subsidiary of Bayer AG, today announced ...
When generating induced pluripotent stem cells (iPSCs) for use in downstream applications, it is commonplace to perform initial checks for key attributes such as viability and pluripotency. This ...
NANJING, China, Oct. 22, 2024 /PRNewswire/ -- HELP Therapeutics Co. Ltd, a clinical-stage cell therapy company, today announced that the U.S. Food and Drug Administration (FDA) has cleared its ...
Phase 1 Clinical Study to Evaluate Multiple Doses of FT538 as Monotherapy for Acute Myeloid Leukemia and in Combination with Anti-CD38 Monoclonal Antibody Therapy for Multiple Myeloma Off-the-shelf NK ...
SAN DIEGO, May 20, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback